The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes by Lisi, Lucia et al.
RESEARCH Open Access
The mTOR kinase inhibitor rapamycin decreases
iNOS mRNA stability in astrocytes
Lucia Lisi
1, Pierluigi Navarra
1, Douglas L Feinstein
2, Cinzia Dello Russo
1*
Abstract
Background: Reactive astrocytes are capable of producing a variety of pro-inflammatory mediators and potentially
neurotoxic compounds, including nitric oxide (NO). High amounts of NO are synthesized following up-regulation of
inducible NO synthase (iNOS). The expression of iNOS is tightly regulated by complex molecular mechanisms,
involving both transcriptional and post-transcriptional processes. The mammalian target of rapamycin (mTOR)
kinase modulates the activity of some proteins directly involved in post-transcriptional processes of mRNA
degradation. mTOR is a serine-threonine kinase that plays an evolutionarily conserved role in the regulation of cell
growth, proliferation, survival, and metabolism. It is also a key regulator of intracellular processes in glial cells.
However, with respect to iNOS expression, both stimulatory and inhibitory actions involving the mTOR pathway
have been described. In this study the effects of mTOR inhibition on iNOS regulation were evaluated in astrocytes.
Methods: Primary cultures of rat cortical astrocytes were activated with different proinflammatory stimuli, namely a
mixture of cytokines (TNFa, IFNg, and IL-1b) or by LPS plus IFNg. Rapamycin was used at nM concentrations to
block mTOR activity and under these conditions we measured its effects on the iNOS promoter, mRNA and protein
levels. Functional experiments to evaluate iNOS activity were also included.
Results: In this experimental paradigm mTOR activation did not significantly affect astrocyte iNOS activity, but
mTOR pathway was involved in the regulation of iNOS expression. Rapamycin did not display any significant
effects under basal conditions, on either iNOS activity or its expression. However, the drug significantly increased
iNOS mRNA levels after 4 h incubation in presence of pro-inflammatory stimuli. This stimulatory effect was
transient, since no differences in either iNOS mRNA or protein levels were detected after 24 h. Interestingly,
reduced levels of iNOS mRNA were detected after 48 hours, suggesting that rapamycin can modify iNOS mRNA
stability. In this regard, we found that rapamycin significantly reduced the half-life of iNOS mRNA, from 4 h to 50
min when cells were co-incubated with cytokine mixture and 10 nM rapamycin. Similarly, rapamycin induced a
significant up-regulation of tristetraprolin (TTP), a protein involved in the regulation of iNOS mRNA stability.
Conclusion: The present findings show that mTOR controls the rate of iNOS mRNA degradation in astrocytes.
Together with the marked anti-inflammatory effects that we previously observed in microglial cells, these data
suggest possible beneficial effects of mTOR inhibitors in the treatment of inflammatory-based CNS pathologies.
Background
Astrocyte activation has been implicated in the patho-
genesis of several neurological conditions, such as neu-
rodegenerative diseases, infections, trauma, and
ischemia. Reactive astrocytes are capable of producing a
variety of pro-inflammatory mediators, including inter-
leukin-6 (IL-6), IL-1b, tumor necrosis factor-a (TNF-a),
neurotrophic factors [1], as well as potentially
neurotoxic compounds, like nitric oxide (NO). NO, one
of the smallest known bioactive products of mammalian
cells, is biosynthesized by three distinct isoforms of NO
synthase (NOS): the constitutively expressed neuronal
(n)NOS and endothelial (e)NOS, and the inducible (i)
NOS [2]. The expression of iNOS can be induced in dif-
ferent cell types and tissues by exposure to immunologi-
cal and inflammatory stimuli [3]. In vitro, primary
astrocyte cultures express iNOS in response to cytokines
such as IL-1b [4], interferon g (IFNg), TNFa and/or the
bacterial endotoxin, lipopolysaccharide (LPS) [5,6]. Once
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which is terminated by enzyme degradation, depletion
of substrates, or cell death [7]. iNOS activity generates
large amounts of NO (within the μMr a n g e )t h a tc a n
have antimicrobial, anti-atherogenic, or apoptotic
actions [8]. However, aberrant iNOS induction exerts
detrimental effects and seems to be involved in the
pathophysiology of several human diseases [9,10].
Consistently, the expression of iNOS is tightly regu-
lated by complex molecular mechanisms, involving both
transcriptional and post-transcriptional processes [2]. At
the post-transcriptional level an important mechanism
of regulation is the modulation of iNOS mRNA stability
that is controlled by several RNA binding proteins
(RNA-BPs) [11]. These proteins bind to the iNOS
mRNA and allow its interaction with the exosome, the
mRNA degrading machinery [2]. Interestingly, the mam-
malian target of rapamycin (mTOR) kinase modulates
t h ea c t i v i t yo fs o m eo ft h ea b o v em e n t i o n e dR N A - B P s
[12,13] mTOR is a serine-threonine kinase that plays an
evolutionary conserved role in the regulation of cell
growth, proliferation, survival, and metabolism, as well
as of other physiological processes such as transcription,
mRNA turnover and protein translation [14]. Within
the cells, mTOR can exist in at least two distinct com-
plexes together with different partners, mTORC1 and
mTORC2. The mTORC1 consists of the regulatory-
associated protein of mTOR, Raptor, and the adaptor
protein mLST8/GbL( Gp r o t e i nb-subunit-like protein),
and regulates several functions related to cell cycle and
growth. The mTORC2 includes mLST8, the adaptor
protein Rictor, and Sin1 [15]. mTORC2 is thought to
regulate the actin cytoskeleton dynamics [16]. Indeed,
rapamycin is a second generation immunosuppressant
drug that blocks T-cell proliferation by inhibition of
mTOR activity, and it is normally used to prevent trans-
plant rejection in association with the older calcineurin
inhibitors [17] mTORC1 activity is inhibited by rapamy-
cin and its analogs, while mTORC2 is insensitive to the
rapamycin inhibitory actions at least at immunosuppres-
sive concentrations [18].
mTOR is also a key regulator of intracellular processes
in glial cells, in fact various mTOR upstream regulators
have been reported to play an important role in astro-
cyte physiology. For example, inactivation of a negative
regulator of the mTOR pathway, the tumor suppressor
PTEN, promotes astrocyte hypertrophy and proliferation
[14]; inactivation of the tumor suppressor tuberin leads
to glial cell hypertrophy and formation of glial hamarto-
mas [14]; up-regulation of mTOR signaling regulates
glutamate transporter 1 [19]; and down-regulation of
mTOR/S6 kinase pathway contributes to astrocyte survi-
val during ischemia [20]. We recently showed that rapa-
mycin and its analog, RAD001, reduce iNOS expression
and activity in microglial cultures activated by pro-
inflammatory cytokines while displaying minor effects
on astrocyte iNOS [21], thus suggesting that mTOR reg-
ulates glial inflammatory activation but with selective
effects. However, with respect to iNOS expression, both
stimulatory and inhibitory actions involving the mTOR
pathway have been described. In particular, rapamycin
has been found to down-regulate LPS-induced iNOS
protein expression in the mouse macrophage RAW
264.7 cell line via mTOR dependent proteasomal activa-
tion [22]. In contrast, TNF-a increases iNOS expression
and NO production in myoblasts via the activation of
the ILK/Akt/mTOR and NFkB signaling pathway [23];
and ultra-sound stimulationu p - r e g u l a t e si N O Se x p r e s -
sion by an HIF-1a-dependent mechanism involving the
activation of ILK/Akt and mTOR pathways via integrin
receptor in osteoblasts [24]. Thus, mTOR differentially
regulates iNOS activity and expression depending on
the cell type or activating stimulus, and this may explain
the different effects that we observed on glial iNOS [21].
In our previous studies, we observed that although
rapamycin reduced iNOS expression mRNA and activity
in microglial cells, and was without effect on astrocyte
iNOS activity [21], it caused a rapid significant increase
in iNOS mRNA levels in astrocytes induced by two dif-
ferent proinflammatory stimuli. Later time points were
not examined; neither was the basis for this contrasting
result examined. In the present paper we tested the
hypothesis that while at early times rapamycin increases
iNOS mRNA, at later times it modifies iNOS mRNA
stability. Our results using primary rat astrocytes are
consistent with this hypothesis, and suggest that inhibi-
tion of mTOR kinase activity in glial cells results in
anti-inflammatory actions. Together with the marked
anti-inflammatory effects observed in microglial cells
[21], these data further provide pre-clinical evidence for
a possible clinical use of mTOR inhibitors in the treat-
ment of inflammatory-based CNS pathologies.
Methods
Materials
Cell culture reagents [Dulbecco’s modified Eagle’sm e d -
ium (DMEM), DMEM-F12 and Fetal calf serum (FCS)]
were from Invitrogen Corporation (Paisley, Scotland).
Antibiotics were from Biochrom AG (Berlin, Germany).
Bacterial endotoxin LPS (Salmonella typhimurium) was
from Sigma-Aldrich (St. Louis, MO, USA). Recombinant
pro-inflammatory cytokines, namely human tumor
necrosis factor a (TNFa), human interleukin-1b (IL-1b)
and rat interferon-g (IFNg) were purchased from Endo-
gen (Pierce Biotechnology, Rockford, IL, USA). Rapamy-
cin (RAPA) was purchased from Tocris Bioscience
(Bristol, UK). b-actin (clone AC-74) mouse monoclonal
antibody was from Sigma Aldrich; rabbit polyclonal anti-
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Biological (Littleton, CO, USA), mouse monoclonal
iNOS antibody was from Santa Cruz (Santa Cruz, CA).
Cell cultures
Primary cultures of rat cortical astrocytes were prepared
as previously described [25]. In brief, 1- to 2-day-old
Wistar rats were sacrificed. The brains were removed
under aseptic conditions and placed in phosphate buffer
saline with Ca
++ and Mg
++ (PBS-w), containing antibio-
tics (100 IU/ml of penicillin plus 100 μg/ml streptomy-
cin). Under a stereomicroscope, the meninges were
carefully removed and the cortex was dissected. The tis-
sue was cut into small fragments, digested with trypsin
in PBS without Ca
++ and Mg
++ (PBS-wo), for 25 min at
37°C and for further 5 min in the presence of DNAse I.
This step was followed by mechanically dissociation in
Dulbecco’s MEM with Glutamax-I containing 10% fetal
calf serum (FCS) and antibiotics as above, to obtain sin-
gle cells. Cell viability was roughly 45%.
The cells thus obtained were seeded in 75-cm
2 flasks at
ad e n s i t yo f1×1 0
7 cells/10 ml (1 brain/flask) and incu-
bated at 37°C in a humidified atmosphere containing 5%
CO2. The medium was changed after 24 h and then twice
a week. Astrocytes obtained with this procedure were then
subcultured twice, the first time in 75-cm
2 flasks and the
second time directly in multiwell plates used for the
experimental procedures. All the experiments were carried
out in 1% FCS DMEM with antibiotics.
C6 glioma cells and stable transfected C6 cells (see
below) were grown in DMEM containing 10% fetal calf
serum and antibiotics, including G418. Cells were
passed once a week and used for the experiments after
3-4 days, when they reached 90% confluence.
Nitrite assay
NOS2 activity was assessed indirectly by measuring
nitrite accumulation in the incubation media. Briefly, an
aliquot of the cell culture media (80 μL) was mixed with
40 μL Griess Reagent (Sigma Aldrich) and the absor-
bance measured at 550 nm in a spectrophotometric
microplate reader (PerkinElmer Inc., MA, USA). A stan-
dard curve was generated during each assay in the range
of concentrations 0-100 μMu s i n gN a N O 2 (Sigma
Aldrich) as standard. In this range, standard detection
resulted linear and the minimum detectable concentra-
tion of NaNO2 was ≥ 6.25 μM.
In the absence of stimuli, basal levels of nitrites were
below the detection limit of the assay after 24 and 48 h
incubations.
iNOS promoter luciferase assay
C6-2.2. cells stably transfected with a 2,168-bp fragment
of the rat iNOS promoter driving luciferase expression
[26] were used to monitor effects of rapamycin on acti-
vation of the iNOS promoter. These cells have a low
level of basal luciferase activity, which can be induced
b e t w e e n4 -a n d1 0 - f o l du p o ni n c u b a t i o nw i t hL P Sp l u s
IFNg or with TII. C6-2.2. cells were incubated with the
indicated iNOS inducers in DMEM containing 1% FCS
and the indicated concentrations of rapamycin. After
desired incubation times, the media were removed, and
the cells were washed once with cold phosphate-buf-
fered saline. To prepare lysates, 50 μlo fC H A P Sb u f f e r
(10 mM CHAPS, 10 mM Tris, pH 7.4) were used. Ali-
quots of cell lysates (40 μl) were placed into wells of an
opaque white 96-well microplate. A volume of luciferase
substrate (20 μl) (Steady Glo reagent, Promega) was
added to all samples, and the luminescence was mea-
sured in a microplate luminometer (Rosys-Anthos, Aus-
tria). The data are presented as the percentage of
luciferase activity measured in the presence of NOS2
inducers and rapamycin, relative to the activity of con-
trol cells (incubated in media with TII).
iNOS mRNA analysis in real time PCR
Total cytoplasmic RNA was extracted from astrocytes
using TRIZOL (Invitrogen). RNA concentration was
measured using the Quant-iT™ RiboGreen
® RNA Assay
Kit (Invitrogen). In each assay, a standard curve in the
range of 0-100 ng RNA was run using 16S and 23S
ribosomal RNA (rRNA) from E. coli as standard. Ali-
quots (1 μg) of RNA were converted to cDNA using
random hexamer primers and the ImProm-II Reverse
Transcriptase (Promega, Madison, WI, USA). Quantita-
tive changes in mRNA levels were estimated by real-
time PCR (Q-PCR) using the following cycling condi-
tions: 35 cycles of denaturation at 95°C for 20 s; anneal-
ing at 59°C for 30 s; and extension at 72°C for 30 s;
Brilliant SYBR Green QPCR Master Mix 2× (Stratagene,
La Jolla, CA, USA) was used. PCR reactions were carried
out in a 20 μL reaction volume in a MX3000P real time
PCR machine (Stratagene). The primers used for iNOS
detection were: 1704F (50-CTG CAT GGA ACA GTA
TAA GGC AAA C-30), and 1933R (50-CAG ACA GTT
TCT GGT CGA TGT CAT GA-30), which yield a 230
base pair (bp) product. The primers used for a-tubulin
were: F984 (50-CCC TCG CCA TGG TAA ATA CAT-
30), and 1093R (50-ACT GGA TGG TAC GCT TGG
TCT-30), which yield a 110 bp product. The primers
used for TTP detection were: 2F (5’- CAG CCT GAC
TTC TGC GAA CCG A -3’), 102R (5’- TGG CTC ATC
GAC ATA AGG CTC TCG T -3’), which yield a 101
base pair (bp) product. The primers used for KSRP
were: 202F (5’- CCG GGG ATA CGC AAG GAC GC
-3’), 472R (5’- CCA CCA TGC CGT CCG GAA CC -3’),
which yield a 271 bp product. The primers used for
HuR detection were: 512F (5’-A A CC C CC G GG T T
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TGC CGG GG -3’), which yield a 216 base pair (bp)
product. Relative mRNA concentrations were calculated
from the take-off point of reactions (threshold cycle, Ct)
using the comparative quantization method and the soft-
ware included in the unit. For this analysis, controls were
used as calibrators and the Ct values for a-tubulin
expression as normalizers. Thus, using the -ΔΔCt
method, we calculated the differences (fold changes) in
the expression of NOS2 target gene after a specific treat-
ment vs. its respective control [27]. Moreover, in each
run we calculated the PCR efficiency using serial dilution
of one experimental sample; efficiency values were found
between 94 and 98% for each primer set [21].
To test the hypothesis that rapamycin could be influ-
encing iNOS mRNA stability, cells were incubated with
TII or TII plus rapamycin for 6 h. Then, 4 μg/ml actino-
mycin D was added and RNA was prepared at time
points from 0 to 4 h thereafter. Relative iNOS and a-
tubulin mRNA amounts were determined by Q-PCR
and iNOS mRNA was normalized versus a-tubulin
mRNA. The relative amount of iNOS mRNA at 0 h was
taken as 100%, and the amount at later time point
reported as percentage of the 0 h time point.
Western immunoblot
Astrocytes were lysed in RIPA buffer (1 mM EDTA, 150
mMNaCl, 1% igepal, 0.1% SDS, 0.5% sodium deoxycho-
late, 50 mM Tris-HCl, pH 8.0) (Sigma-Aldrich) contain-
ing protease inhibitor cocktail diluted 1:250 (Sigma-
Aldrich). The protein content in each sample was deter-
mined by Bradford’s method (Biorad, Hercules, CA,
USA) using bovine serum albumin as standard. A 20 μg
aliquot of protein was mixed 1:2 with 2× Laemmli Buf-
fer (Biorad), boiled for 5 min, and separated through
10% polyacrylamide SDS gels. Apparent molecular
weights were estimated by comparison to colored mole-
cular weight markers (Sigma Aldrich). After electrophor-
esis, proteins were transferred to polyvinylidene
difluoride membranes by semi-dry electrophoretic trans-
fer (Biorad). The membranes were blocked with 10%
(w/v) low-fat milk in TBST (10 mM Tris, 150 mMNaCl,
0.1% Tween-20, pH 7.6) (Biorad) for 1 h at room tem-
perature, and incubated in the presence of the primary
antibody overnight with gentle shaking at 4°C. Primary
antibodies for phosphorylated mTOR, b-actin were used
at the final concentration of 1:1000; primary antibody
for iNOS were used at the final concentration 1:400. Pri-
mary antibodies were removed, membranes washed 3
times in TBST, and further incubated for 1h at room
temperature in the presence of specific secondary anti-
body, anti-rabbit IgG-HRP conjugated (Vector Labora-
tories, Burlingame, CA, USA) diluted 1:15,000-20,000 or
anti-mouse IgG-HRP conjugated (Sigma-Aldrich)
secondary antibody, diluted 1:20,000. Following three
washes in TBST, bands were visualized by incubation in
ECL reagents (GE Healthcare) and exposure to Hyper-
film ECL (GE Healthcare NY, USA). The same mem-
branes were washed 3 times in TBST, blocked with 10%
(w/v) low-fat milk in TBST for 1 h at room temperature
and used for b-actin immunoblot. Band intensities were
determined using ImageJ software (National Institutes of
Health) from autoradiographs obtained from the mini-
m u me x p o s u r et i m et h a ta l l o wb a n dd e t e c t i o n ,a n d
background intensities (determined from an equal-sized
area of the film immediately above the band of interest)
were subtracted.
Data analysis
All experiments were done using 5-6 replicates per each
experimental group, and repeated at least 3 times. For
the RNA analysis, samples were assayed in triplicates,
and the experiments were repeated at least twice. Data
were analyzed by one- or two-way ANOVA followed by
Bonferroni’s post hoc tests or by unpaired t-test P values
< 0.05 were considered significant.
Results
Cytokine dependent mTOR activation does not
significantly affect astrocyte iNOS activity
Astrocytes were stimulated using a mixture of proin-
flammatory cytokines (TII), i.e. 10 ng/ml IL1b, 10 ng/ml
TNFa,5n g / m lI F N g, and the activation of the mTOR
pathway was examined by measurement of the phos-
phorylation level of mTOR at Ser2448 [21]. Cells were
incubated for 2 h, and then subjected to protein analysis
for phospho-mTOR and b-actin. TII significantly
increased mTOR phosphorylation at Ser2448, which was
completely blocked by10 nM rapamycin (Figure 1). Sig-
nificant amounts of nitrites, a stable end product of NO,
could be measured after 48 h incubation and were sig-
nificantly increased by TII [21]. However, while rapamy-
cin significantly reduced iNOS expression and activity in
microglial cells, it displayed only minor effects on TII
stimulated astrocytes [[21], Figure 2A]. In particular,
rapamycin within the 0-10 nM range tended to reduce
TII dependent NO production, but this effect did not
reach statistical significance (Figure 2A). Similarly, rapa-
mycin failed to inhibit NO production when astrocytes
were exposed to another pro-inflammatory stimulus that
is more widely used in vitro to activate glial cells,
namely 1 μg/ml LPS and 5 ng/ml IFNg (LI) (Figure 2B).
The modest effects of rapamycin on iNOS activity
were confirmed by western blot analysis. Under basal
conditions, astrocytes do not express iNOS, but protein
levels are significantly increased by 24 h stimulation in
presence of either TII or LPS (Figure 3A). However,
protein levels of iNOS measured after 24 h treatment
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similar (Figure 3B, C). Together these data confirm our
previous findings that in contrast to microglia cells,
rapamycin has little effect on iNOS protein expression
or activity.
The mTOR pathway is involved in the regulation of iNOS
expression
The steady state levels of iNOS mRNA were almost
undetectable by Q-PCR under basal conditions (average
Ct≈31), and increased in response to TII, with statisti-
cally significant increases observed after 2 h incubation,
maximum levels detected after 4 h, and persistent eleva-
tion up to 48 h (the latest time point analyzed, (Figure
4A). Under these conditions, 10 nM rapamycin signifi-
cantly increased iNOS mRNA levels between 4 h and 12
h incubation (Figure 4A). However, the stimulatory
effect of rapamycin was transient, since no differences in
iNOS mRNA were detected after 24 h between cells
treated with TII and cells co-incubated with rapamycin;
while after 48 h rapamycin caused significant reduction
in iNOS mRNA levels (Figure 4A). The up-regulation of
iNOS mRNA due to rapamycin did not directly translate
into increased iNOS activity, since only a slight increase
in nitrite production was measured in astrocytes co-
treated with TII and 10 nM rapamycin for 24 h com-
pared to TII alone (Figure 4B). Similarly, 10 nM rapa-
mycin significantly increased the stimulatory effect of LI
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Figure 1 Rapamycin reduces mTOR phosphorylation induced
by TII. (A) Whole-cell lysates were prepared from astrocytes
activated with TII for 2 h. 10 nM Rapamycin was added at the
beginning of the experiment and equal amounts of protein were
analyzed by western blot for phosphorylated mTOR kinase (p-mTOR)
(upper gel) and consequently for b-actin (lower gel). (B)
Quantitation of densitometry wherein p-mTOR values are reflected
relative to those for b-actin. Data are representative of two different
experiments. Results were analyzed by one-way ANOVA followed by
Bonferroni’s post-test. *P < 0.05 vs. Controls; °P < 0.05 vs. TII.
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Figure 2 Effects of the mTOR inhibitor on NO production in
activated astrocytes. Astrocytes were activated for 48 h with TII
[Figure 2A] or 24 h with LI [Figure 2B]. The mTOR inhibitor,
rapamycin was added to the cells in nM concentrations at the
beginning of the experiments. NO production was assessed
indirectly by measurement of nitrite accumulation in the incubation
medium (Griess method). Data are expressed as means ± SEM (n =
6). Data are representative of 3 different experiments. Results were
analyzed by one-way ANOVA followed by Bonferroni’s post-test.
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Figure 3 Rapamycin does not modify the level of iNOS protein.
(A) Whole-cell lysates were prepared from Control astrocytes or cells
activated with TII or LPS for 24 h. Equal amounts of proteins were
analyzed by western blot for iNOS (upper gel) and consequently for
b-Actin (lower gel). Two replicates per each experimental group are
shown in the gel. (B) Pro-inflammatory cytokines (TII), and/or 10 nM
Rapa were added at the beginning of the experiment and proteins
were analyzed as described above. (C) Quantification of
densitometry wherein iNOS values are reflected relative to those for
b-actin. Data are representative of two different experiments.
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after 24 h incubations (Figure 5B). Rapamycin alone did
not have any significant stimulatory effect per se on
either iNOS activity or on its expression (data not
shown).
Extensive characterization of glial iNOS expression
and regulation has been carried out with the rat C6
glioma cell line, which shares many properties with
primary astrocyte cultures, including expression and
regulation of the iNOS gene, mRNA and protein
[6,28]. Using C6 cells stably transfected with a 2.2 kB
rat iNOS promoter, we observed that TII increased the
promoter activity of iNOS, with a maximum signal
detected after 8 h incubation. Promoter activation
lasted up to 24 h, the longest time point studied (Fig-
u r e6 A ) .T h u s ,t h e8ht i m ep o i n tw a sc h o s e nf o rs u b -
sequent studies carried out to characterize the effects
of rapamycin on iNOS promoter activity. For this,
rapamycin was added at the beginning of the experi-
ment, and after 8 h cells were washed with cold PBS
and luciferase activity measured. Rapamycin, even at
10 times lower concentration, significantly increased
iNOS promoter activity in comparison to cells treated
with TII alone (Figure 6B). This increase of iNOS pro-
moter activity elicited by the mTOR inhibitor may
help account for the stimulatory effects of rapamycin
on iNOS mRNA levels observed at earlier time points
in astrocytes. However, in contrast to primary astro-
cytes, rapamycin dose and time-dependently increased
n i t r i t ep r o d u c t i o ni nC 6cells (Figure 7A, B), which
suggests that additional regulatory factors are induced
in astrocytes which restrict iNOS activity.
mTOR kinase regulates the rate of iNOS mRNA
degradation
The above results suggested that rapamycin could be
influencing iNOS mRNA stability. To test this possibi-
lity, the levels of iNOS mRNA were quantified in pri-
mary astrocytes after different times in the presence of
TII alone or with actinomycin D added after 6 hr incu-
bation with TII (Figure 8). The half-life of iNOS mRNA
after TII treatment was determined to be 4 h, and was
significantly reduced to less than 1 hour by the presence
of rapamycin (Figure 8). Moreover, after 6 hr incubation
in TII, rapamycin significantly increased the expression
of tristetraprolin (TTP), a protein involved in iNOS
mRNA stabilization (Figure 9A). In contrast, rapamycin
did not modify levels of two other proteins that regulate
mRNA stability, namely the KH-type splicing regulatory
protein (KSRP) (Figure 9B) and HuR (Figure 9C).
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Figure 4 Effects of the mTOR inhibitor on iNOS expression elicited by TII. (A) Total cytosolic RNA was prepared from Control, or astrocytes
treated with TII and rapamycin for different times, and used for Q-PCR analysis of iNOS expression. Data are expressed as fold change vs. each
respective Control, taken as calibrator for comparative quantitation analysis of mRNA levels. Each sample was measured in triplicate, the
experiment was repeated 2 times with similar results. Where indicated, 10 nM Rapamycin was added at the beginning of the experiment. In all
time points TII significantly induced iNOS expression in comparison to Controls and rapamycin increases in 4 h the iNOS mRNA expression
elicited by TII. Data are means ± SEM (n = 3). *P < 0.05, **P < 0.01, and *** P < 0.001 vs. TII; two-way ANOVA followed by Bonferroni’s post-test.
(B) Nitrite production elicited by TII was assessed at different time points, 10 nM rapamycin was added together with cytokines at beginning of
experiment. Data are means ± SEM (n = 4). **P < 0.01, vs. Controls; and
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In the present study we studied the involvement of the
mTOR pathway during pro-inflammatory activation of
rat cortical astrocytes in response to two different pro-
inflammatory stimuli, namely a mixture of cytokines
("TII”) and the bacterial endotoxin LPS augmented with
IFNg ("LI”). Moreover, the pharmacological inhibition of
mTOR obtained using 10 nM rapamycin up-regulated
iNOS mRNA levels without any relevant effect on iNOS
activity. This opposite result is explained by the parallel
increase in the rate of iNOS mRNA degradation asso-
ciated with the inhibition of mTOR kinase. Rapamycin
treatment did not interfere with astrocyte viability or
proliferation, as we previously reported [21]. These find-
ings clearly indicate that the blocking of mTOR pathway
is crucial for the production of NO, and that the overall
effect observed can be regarded as anti-inflammatory
since the up-regulation of iNOS was compensated with
increased iNOS degradation machinery activity.
The possible involvement of mTOR during pro-inflam-
matory astrocyte activation was studied by direct evalua-
tion of the levels of mTOR phosphorylation at Ser2448 in
presence of proinflammatory cytokines [21]. Phosphory-
lation at Ser2448 is a marker of mTOR pathway activa-
tion, as suggested by the finding of Rosner and
collaborators that down-regulation of mTOR kinase
ser2448 phosphorylation correlates with decreased
mTORC1 activity [29]. In our experimental conditions,
phospho-mTOR at Ser2448 was increased by TII and
rapamycin completely abolished the phosphorylation,
suggesting that proinflammatory activation of astrocytes
involves the recruitment of the mTOR pathway in a rapa-
mycin sensitive manner (Figure 1), suggesting that the
drug can reduce astrocyte proinflammatory activation.
Usually under inflammatory conditions, high levels of
NO are generated by the up-regulation of iNOS. The
protein can be induced by different proinflammatory sti-
muli to different extents. In general, LPS is a more
robust activator, thus nitrite levels (an indirect measure
of iNOS activity) are significantly elevated after 24 h
incubation, whereas in the presence of pro-inflammatory
cytokines (TII) a significant increase in nitrite levels is
generally detectable after 48 h incubation. These data
may be explained by the recruitment of different signal-
ing pathways by the two stimuli, and or by a different
timing in recruitment, as happens in microglial cells
[21]. Regardless of the stimulus used, rapamycin did not
modify nitrite levels (Figure 2), while it was able to
increase the amount of iNOS mRNA at the earlier time
points. This up-regulation was transient, because such
differences were absent at 24 h (Figure 4 and 5) and a
s i g n i f i c a n tr e d u c t i o nw a so b s e r v e da t4 8h( F i g u r e4 A ) .
Rapamycin alone did not display pro-inflammatory
effects per se, being unable to increase either iNOS
mRNA levels or nitrite production after 4 and 24 h
incubations (data not shown).
The expression of iNOS is tightly regulated by both
transcriptional and post-transcriptional mechanisms.
This includes regulation of iNOS promoter activity by
binding of transcription factors (NFkB, STAT-1a)a n d
the modulation of iNOS mRNA expression. Post-tran-
scriptional regulation of gene expression is often depen-
dent on sequences located in the 3’-untraslated region
(3’-UTR) of mRNAs [30]. AU-rich (ARE) elements have
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expression elicited by LI. Total cytosolic RNA was prepared from
Control, or astrocyte cells treated LI and rapamycin for different
times, and used for Q-PCR analysis of iNOS expression. Data are
expressed as fold change vs. each respective Control, taken as
calibrator for comparative quantitation analysis of mRNA levels.
Astrocytes were treated for 4 h (A) or 24 h (B). Each sample was
measured in triplicate, the experiment was repeated 2 times with
similar results. Where indicated, 10 nM Rapamycin was added at the
beginning of the experiment. LI significantly induced iNOS
expression in comparison to Controls and rapamycin increases in 4
h the iNOS mRNA expression elicited by LI. Data are means ± SEM
(n = 3).
§§P < 0.01 vs. LI *P < 0.05 vs. Controls; one-way ANOVA
followed by Bonferroni’s post-test.
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the incubation times the luciferase activity was measured. (B) Cells
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separate cell cultures; results were analyzed by unpaired t-test.
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Page 7 of 11been shown to confer destabilization of mRNAs coding
for pro-inflammatory proteins or oncogenes [31]. In
mammalian cells, ARE mediates mRNA decay mainly by
recruitment of the exosome to the mRNAs, thereby pro-
moting their rapid degradation. However, the mamma-
lian exosome does not seem to recognize the ARE-
containing RNAs on its own but requires certain ARE
binding protein (ARE-BPs) for this interaction. In parti-
cular in untreated cells the RNA-Binding Protein (RNA-
BP) KH-type splicing regulatory protein (KSRP) or the
zinc-finger protein tristetraprolin (TTP) binds the iNOS
mRNA 3’-UTR and recruits the exosome to the mRNA
[32]. This results in rapid iNOS mRNA degradation.
KSRP binds to the same ARE as HuR, another RNA-BP
that oppositely stabilizes the mRNA, and both RNA-BPs
compete for this binding sites [33]. After cytokine-treat-
ment, p38 MAP kinase is activated and TTP expression
is enhanced. The protein-protein interactions between
TTP and KSRP compete for the same binding site in
the iNOS 3’-UTR sequence, causing dislodgment of
KSRP and enhanced HuR binding to the iNOS mRNA.
The reduced KSRP and the enhanced HuR binding to
the iNOS mRNA 3’UTR result in marked stabilization
of the iNOS mRNA and thus in enhanced iNOS expres-
sion. Similarly, in our experimental model TII was
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or with TII plus 10 nM rapamycin for 6 h. After the pretreatment,
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indicated. Cells were harvested at designated time points, total RNA
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PCR. The mRNA level at 0 time point (before the treatment with
actinomycin D) was considered as 100%. Data are representative of
3 independent experiments. Data are means ± SEM (n = 3). ***P <
0.05 vs. TII/Rapa 10 nM; one-way ANOVA followed by Bonferroni’s
post-test.
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Page 8 of 11found to significantly increase the levels of these RNA-
BPs (Figure 9), while rapamycin transiently upregulated
the expression of TTP without affecting the other pro-
teins (Figure 9A). It has been shown that TTP may have
opposite effects on mRNA stability in function of the
AKT activation state [12]. Therefore, up-regulation of
TTP in our experimental model may contribute either
to the initial iNOS mRNA stabilization or be responsible
for the subsequent increased rate of mRNA degradation.
Additional experiments are required to completely
address the role of TTP in iNOS mRNA regulation, but
the present data strongly suggest a role for this protein.
Consistent with our data, rapamycin was found to inter-
fere with mRNA degradation in different cell types. For
example in renal epithelial cells, Pallet and collaborators
showed that rapamycin inhibits cell proliferation by
regulating the expression and stability of cyclin D3
mRNA [34]. In fibroblasts rapamycin inhibition of G1 to
S transition is mediated by an effect on cyclin D1
mRNA and protein stability [35]. Maderosian and col-
leagues showed that rapamycin regulates cyclin D1 and
c-Myc mRNA in different types of tumor cells involving
an enhancement of TTP binding activity [12]. Recently,
Basu and collaborators demonstrated that the immuno-
suppressant drugs, cyclosporine and rapamycin, regulate
VEGF mRNA stability in opposite manners. While
cyclosporine enhances mRNA stability by induction of
the RNA-BP, HuR, rapamycin increases the rate of
degradation in renal cancer cells [13]. In summary,
there is increasing evidence that rapamycin can regulate
the activity of RNA-BPs, thus interfering with the stabi-
lity of different mRNAs.
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Page 9 of 11In our experimental paradigm, rapamycin increased the
rate of iNOS mRNA degradation. In particular, using
actinomycin D to block mRNA transcription, we found
that after induction of iNOS mRNA by TII the degrada-
tion of iNOS mRNA occurs with a half life of about 4 h.
Activation of astrocytes in the presence of rapamycin was
characterized by an increased rate of degradation (t1/2. ≈
5 0m i n ) ,w h i c hm a yb em e d i a t e db yu p - r e g u l a t i o no f
mRNA destabilizing proteins as occurs in other cell types
[12,13]. The net effect of these complex actions on the
regulation of iNOS mRNA result in similar levels of pro-
tein expression and in-significant differences in the
amount of NO generated in TII-activated astrocytes in
the presence or absence of rapamycin.
Conclusions
Our findings suggest that rapamycin does not directly
exert pro-inflammatory actions in rat primary cultures
astrocytes, nor does it increase the proinflammatory
effects of cytokines or LPS. In fact, the iNOS mRNA
up-regulation induced by rapamycin administered
together with a proinflammatory stimuli appears to be
transient and accompanied by an increased rate of iNOS
mRNA degradation. Such effects do not augment iNOS
protein levels (Figure 3) nor the amount of nitrite pro-
duction to any significant extent. Together with the
marked anti-inflammatory effects observed in microglial
cells [21], these data suggest possible beneficial effects
of mTOR inhibitors in the chronic treatment of inflam-
matory-based CNS pathologies.
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